Spruce Biosciences, Inc. Increase (Decrease) in Accounts Receivable
Spruce Biosciences, Inc. (SPRB) reported Increase (Decrease) in Accounts Receivable of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2024-05-13
- Spruce Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was $15.00M.
- Spruce Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2022-03-31 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month |
|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 |
| 2023-03-31 | $15.00M 10-Q · filed 2024-05-13 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |